Executive Summary
Within just a few years, the convergence of healthcare real estate and logistics infrastructure has moved from a niche topic to a stand-alone asset class. Pharmaceutical distribution centres with cold-chain capabilities, medical supply hubs, laboratory cross-docks and temperature-controlled last-mile nodes today secure lease terms of 12 to 20 years, indexed, with investment-grade tenants. For institutional investors this translates into defensive cash flow, structural tailwinds from demographics and reshoring, and a yield premium of around 75 to 150 basis points over prime logistics in Western European core markets (CBRE European Logistics Market Snapshot Q1 2026).
Prime East focuses precisely on this segment in Central and Eastern Europe, where the yield spread is wider, rental growth is more dynamic and competition remains markedly thinner than in the DACH region. This article frames the topic, outlines the market drivers and explains why the next 18 to 24 months represent a genuine window of opportunity for co-investments.
What are Healthcare-Logistics Hybrids?
At their core, these are specialised properties that combine two operational logics:
On one side stand the requirements of classic logistics assets motorway and airport connectivity, cross-docking functionality, high turnaround frequency, scalability. On the other side come the regulatory and technical requirements of the healthcare sector: GDP-compliant cold chains (Good Distribution Practice under EU directive 2013/C 343/01), redundant cooling technology with –25 °C to +25 °C zones, clean rooms, validated backup power, access controls and pharma audit trails.
Typical use cases include pharmaceutical wholesale centres (Phoenix, McKesson/Celesio, NMC), distribution nodes for medical devices and diagnostics, cold-chain hubs for mRNA therapeutics and biologics, lab-logistics cross-docks for diagnostic groups (Synlab, Sonic, Diagnostyka), as well as last-mile micro-hubs for online pharmacies (DocMorris, Apotal, Mediq). Hospital groups are increasingly integrating their own supply hubs as well; a pattern long established in the United States (Premier, Vizient) that is now spreading across Europe.
Why Now? Five Structural Drivers
1. Demographics as a Capital-Forming Force
Eurostat projects that the share of the EU population aged 65 and over will rise from 21.3% (2023) to 32.5% by 2050 (Eurostat, Population Structure and Ageing, 2024). In Germany, Italy, Poland and Czechia, ageing is accelerating. The consequence: structurally rising pharmaceutical volumes, more diagnostics, more home-based care, and therefore logistics infrastructure that is not under-utilised but structurally scarce.
2. Reshoring of Pharmaceutical Production
Following the supply-chain disruptions during the pandemic and the weakness of Asian supply chains in 2022–2024, the EU introduced the Critical Medicines Act (European Commission proposal, March 2025), creating a regulatory framework that supports the relocation of critical active ingredient and finished medicine production back to Europe. Poland, Hungary and Ireland are the principal beneficiaries (European Commission, Critical Medicines Act – Impact Assessment, 2025). Each new production site triggers two to three logistics assets within a 50 km radius.
3. Cold-Chain Volumes Are Exploding
According to the Pharmaceutical Commerce Annual Biopharma Cold Chain Sourcebook (2025), the global market for pharmaceutical cold-chain logistics is forecast to grow from USD 21.3 billion (2024) to USD 36.1 billion (2029) – an 11.1% CAGR. Drivers include biologics, cell and gene therapies and GLP-1 compounds (Ozempic, Wegovy, Mounjaro), which have already led to significant capacity shortfalls in cold-storage space.
4. Online Pharmacies and Tele-Diagnostics
With the introduction of the e-prescription in Germany (mandatory since 2024) and comparable programmes in Poland (e-recepta) and Czechia, online dispensing of medicines has reached a new structural level. JLL estimates the growth of specialised pharma last-mile space in Europe at around 18% per year between 2023 and 2026 (JLL, European Healthcare Logistics – Market Perspective, Q4 2025).
5. ESG Alignment by Design
Healthcare logistics is increasingly recognised – under SFDR Article 9 and the EU Taxonomy – as socially essential infrastructure. Continuity of pharmaceutical supply is explicitly cited as a socially sustainable investment in several national taxonomy interpretations. For institutional mandates – insurers, ecclesiastical trusts, pension funds; this has become an increasingly decisive allocation factor.
Investment Thesis: What Makes These Hybrids Attractive
The economic logic of the asset class rests on four interlocking factors.
Lease quality. Healthcare tenants typically sign triple-net leases with 12 to 20-year terms, indexed to HICP or CPI, with caps or floors. Early termination is effectively excluded, since the regulatory validation of a new site (GMP, GDP, authority approvals) takes twelve to twenty-four months. This translates into a WAULT stability that classic logistics rarely achieves.
Tenant credit. Counterparties are typically global pharmaceutical wholesalers, listed diagnostics groups or municipal hospital operators. Knight Frank reports an average tenant credit rating of BBB+ in its European Healthcare Capital Markets Report 2025 – well above the BB level typical of standard logistics.
Yield profile. According to Savills (European Industrial & Logistics Outlook, Q1 2026), prime yields for healthcare-logistics hybrids in top markets range from 5.25% (Frankfurt, Munich) to 6.75% (Warsaw, Prague) – versus 4.25% to 5.50% for prime logistics in the same markets. The spread reflects a smaller investor base and the specific operational expertise required for acquisition and asset management – not weaker tenant security.
Value resilience in downturns. During the logistics repricing wave of 2022–2024 (yield expansion of around 175 bps in Western Europe, Cushman & Wakefield MarketBeat, 2024), healthcare-logistics assets saw only 90 to 110 basis points of yield expansion – demonstrating significantly higher value resilience.
The CEE Edge: Why Prime East Focuses on Central and Eastern Europe
The region between Berlin and Bucharest combines several structural advantages that are unique in this combination.
First, geographic position as a hub between Western European consumer markets and Eastern European production sites. Poland is now the sixth-largest pharmaceutical market in the EU and one of the three largest centres for contract pharma manufacturing (CMO/CDMO) in Europe (PMR Market Experts, Pharmaceutical Industry in Poland 2025).
Second, rental growth: Cushman & Wakefield reports nominal rental growth for prime logistics in Poland of 6.8% in 2025 – in the healthcare-hybrid segment the figure was around 9% (Cushman & Wakefield, Polish Industrial Market Report, 2025).
Third, the yield gap: with prime yields between 6.25% and 6.75% in Warsaw, Poznań and Prague, return levels are 100 to 150 basis points above comparable assets in Frankfurt or Milan – at comparable tenant credit, since many of the tenants are the same pan-European operators.
Fourth, the pipeline deficit: properties developed specifically to healthcare specifications account for less than 4% of the CEE logistics stock (Prime East estimate based on Colliers and CBRE Q4 2025 datasets). Demand exceeds supply in every relevant submarket.
Reference Transactions 2024–2026
To illustrate the depth of the asset class, here are several publicly disclosed reference transactions:
Panattoni delivered four dedicated pharma cold-storage assets in Łódź, Wrocław and Poznań in 2024 and 2025, with pre-leases including a US-based pharmaceutical 3PL (Panattoni Press Release, Q3 2025). Goodman, together with Phoenix Group, completed an integrated pharmaceutical distribution centre in southern Germany on an 18-year lease (Goodman Group, Annual Report 2025). Prologis expanded its “Healthcare Logistics” portfolio in 2025 with locations in the Netherlands and Czechia (Prologis, Q4 2025 Earnings Release).
On the transaction market, mixed healthcare-logistics portfolios traded at multiples of 16 to 19 according to Real Capital Analytics (versus 14 to 16 for standard logistics in comparable locations).
Risks, and How Prime East Manages Them
A serious investment analysis must also name the weaknesses.
Regulatory risk is real: changes to GDP standards, EU packaging regulations or national pharmacy distribution rights can shift use requirements. Prime East mitigates this through close cooperation with GxP specialist planners during the due diligence phase, and through lease clauses that clearly allocate the costs of regulatory adjustments between landlord and tenant.
Concentration risk on a small number of large tenants is addressed through a deliberate portfolio diversification model: maximum 25% exposure per tenant group, minimum three sub-segments (pharmaceutical wholesale, diagnostics, online pharmacy).
Build-spec risk – the concern that a hybrid asset is hard to re-let – is increasingly disproven empirically: according to JLL (Q4 2025), 87% of expired healthcare leases in Europe were re-let to healthcare tenants within nine months, often at higher rents.
Interest rate risk has receded following the first ECB rate cuts in 2025 but remains relevant. Prime East structurally targets moderate leverage of 45% to 55% LTV with predominantly hedged financing.
What Does This Mean for Institutional and Family Office Investors?
From an allocation perspective, an increasing weight of evidence supports treating healthcare-logistics hybrids as a stand-alone sub-class within “Operational Real Estate” or “Beds & Sheds” allocations – not as an appendix to classic logistics portfolios.
Performance correlation with pure office or residential segments is low. Correlation with pharma equities is surprisingly modest, since lease income depends on volume flows rather than operating margins. Regulatory complexity functions as a market-entry barrier for generalists – which is precisely why specialised platforms such as Prime East can sustainably capture the yield spread.
Prime East: Co-Investment Pipeline 2026/2027
Prime East is currently structuring a pipeline of approximately EUR 280 million across eight locations in Poland, Czechia and Romania. The majority of assets are being developed under a forward-funding model, with secured pre-letting ratios of between 70% and 100% prior to construction start.
We invite professional investors – insurers, pension funds, family offices and qualified asset managers – to participate in our Prime East Healthcare Logistics Vehicle II. Target return: 8.5% to 10.5% IRR (net, equity), with a current distribution of 5.0% per annum from stabilisation.
For a confidential introductory conversation and access to the investor data room, please contact us via the contact section of the Prime East website.
Conclusion
The convergence of demographics, reshoring, the cold-chain boom and ESG requirements arguably makes healthcare-logistics hybrids the most compelling risk-adjusted story in European real estate investment in 2026. Central and Eastern Europe offers the most attractive combination of yield, rental growth and pipeline scarcity. Investors who allocate now secure a structural advantage before the yield gap with Western Europe begins to close a process Knight Frank expects to commence within the next 36 months.
Contact us with your insights.
Sources
- CBRE (2026): European Logistics Market Snapshot Q1 2026. https://www.cbre.com/insights
- Cushman & Wakefield (2025): Polish Industrial Market Report 2025. https://www.cushmanwakefield.com
- Cushman & Wakefield (2024): MarketBeat European Industrial Q4 2024. https://www.cushmanwakefield.com/en/insights/marketbeat
- Eurostat (2024): Population Structure and Ageing. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing
- European Commission (2025): Critical Medicines Act – Impact Assessment. https://health.ec.europa.eu/medicinal-products/critical-medicines-act_en
- European Medicines Agency: Guidelines on Good Distribution Practice (2013/C 343/01). https://www.ema.europa.eu
- Goodman Group (2025): Annual Report 2025. https://www.goodman.com/investor-centre
- JLL (2025): European Healthcare Logistics – Market Perspective Q4 2025. https://www.jll.com/en/trends-and-insights
- Knight Frank (2025): European Healthcare Capital Markets Report 2025. https://www.knightfrank.com/research
- Panattoni (2025): Press Releases Q3 2025. https://panattonieurope.com/en/news
- Pharmaceutical Commerce (2025): Annual Biopharma Cold Chain Sourcebook 2025. https://www.pharmaceuticalcommerce.com
- PMR Market Experts (2025): Pharmaceutical Industry in Poland 2025. https://mypmr.pro
- Prologis (2025): Q4 2025 Earnings Release. https://ir.prologis.com
- Savills (2026): European Industrial & Logistics Outlook Q1 2026. https://www.savills.com/research
Disclaimer: This article is provided for informational purposes only and does not constitute investment advice, a public offering or a solicitation to subscribe for securities or fund units. An investment in real estate investment structures involves risks, including the possible loss of invested capital. Past returns are not a reliable indicator of future performance. Detailed information for professional investors is set out in the relevant fund documentation.
© 2026 Prime East. All rights reserved.
